{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:53:51Z","timestamp":1771667631527,"version":"3.50.1"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.pharmthera.2016.04.011","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T11:19:23Z","timestamp":1462015163000},"page":"183-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol"],"prefix":"10.1016","volume":"164","author":[{"given":"Laura A.","family":"Della Badia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil A.","family":"Elshourbagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaker A.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.04.011_bb0005","series-title":"Anti-pcsk9 compounds and methods for the treatment and\/or prevention of cardiovascular diseases","author":"Abdel-Meguid","year":"2014"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0010","series-title":"Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and\/or prevention of cardiovascular diseases.","author":"Abdel-Meguid","year":"2014"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0020","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.phrs.2015.03.009","article-title":"Lipids, blood pressure and kidney update 2014","volume":"95-96C","author":"Banach","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance\u2014an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0035","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s00109-005-0710-0","article-title":"Inhibitors of proprotein convertases","volume":"83","author":"Basak","year":"2005","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0040","first-page":"651","article-title":"Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia","volume":"8","author":"Bell","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0045","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0050","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase (PC) PCSK9 is inactivated by furin and\/or PC5\/6A: Functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060095","article-title":"Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels","volume":"8","author":"Berthold","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0060","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0065","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/cphy.c120027","article-title":"Bile formation and secretion","volume":"3","author":"Boyer","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0070","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0075","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0080","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0085","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists, C.","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0090","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/14740338.2014.932348","article-title":"Safety and tolerability of injectable lipid-lowering drugs: A review of available clinical data","volume":"13","author":"Cicero","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2261-14-121","article-title":"Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: Rationale and design of the ODYSSEY COMBO I and II trials","volume":"14","author":"Colhoun","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1074248414539562","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibitors: An emerging lipid-lowering therapy?","volume":"20","author":"Dragan","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0125","article-title":"The role of nutrients in protecting mitochondrial function and neurotransmitter signaling: Implications for the treatment of depression, PTSD, and suicidal behaviors","volume":"0","author":"Du","year":"2014","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0130","doi-asserted-by":"crossref","first-page":"A9761","DOI":"10.1161\/circ.130.suppl_2.9761","article-title":"Novel modulators of low density lipoprotein receptor metabolism","volume":"130","author":"Elshourbagy","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0135","doi-asserted-by":"crossref","first-page":"A10306","DOI":"10.1161\/circ.132.suppl_3.10306","article-title":"Abstract 10306: Identification and characterization of orally bioavailable small molecule protease proprotein convertase subtilisin-like kexin type 9 inhibitors (Best of Basic Science Abstract)","volume":"132","author":"Elshourbagy","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0140","doi-asserted-by":"crossref","first-page":"A10829","DOI":"10.1161\/circ.132.suppl_3.10306","article-title":"Abstract 10829: Biological and pharmacological properties of the protease proprotein convertase subtilisin-like kexin type 9 antagonists (Best of Basic Science Abstract)","volume":"132","author":"Elshourbagy","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1074248413492906","article-title":"Lipid-lowering agents","volume":"18","author":"Ewang-Emukowhate","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1567-5688(15)50006-8","article-title":"The role of PCSK9 in intestinal lipoprotein metabolism: Synergism of statin and ezetimibe","volume":"17","author":"Fazio","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0155","author":"FDA"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0160","author":"FDA"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0165","author":"FDA"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0170","author":"FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0175","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0180","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0185","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1074248414545127","article-title":"Looking into the crystal ball-upcoming drugs for dyslipidemia","volume":"20","author":"George","year":"2015","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0195","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0200","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.3390\/nu6125517","article-title":"PCSK9 antibodies for the treatment of hypercholesterolemia","volume":"6","author":"Gouni-Berthold","year":"2014","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0205","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0210","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1161\/01.CIR.0000151100.28000.B3","article-title":"Atherosclerosis imaging and the future of lipid management","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0215","first-page":"360","article-title":"GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum","volume":"2014","author":"Hassan","year":"2014","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0220","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11789-015-0071-3","article-title":"Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease","volume":"10","author":"Heigl","year":"2015","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0225","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","article-title":"Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk\u2014primary results from the phase 2 YUKAWA study","volume":"78","author":"Hirayama","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/CIRCRESAHA.116.304637","article-title":"Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein","volume":"116","author":"Hooper","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0235","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: A convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0240","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1743-7075-7-47","article-title":"Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones","volume":"7","author":"Hu","year":"2010","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0250","doi-asserted-by":"crossref","first-page":"11991","DOI":"10.1073\/pnas.93.21.11991","article-title":"An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells","volume":"93","author":"Jamil","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0255","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/1947-2714.153919","article-title":"Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0260","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.amjcard.2014.10.018","article-title":"Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin\/kexin type 9 levels in patients with dyslipidemia","volume":"115","author":"Khera","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0265","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1253\/circj.CJ-14-1329","article-title":"Report of the American Heart Association (AHA) scientific sessions 2014, Chicago","volume":"79","author":"Kohno","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0270","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0275","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0280","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0285","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MOL.0b013e3281338531","article-title":"Unravelling the functional significance of PCSK9","volume":"18","author":"Lambert","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0290","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1586\/14779072.2015.1030395","article-title":"Evolocumab (AMG 145) for primary hypercholesterolemia","volume":"13","author":"Langslet","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0295","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0300","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1194\/jlr.R052415","article-title":"Insights from human congenital disorders of intestinal lipid metabolism","volume":"56","author":"Levy","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0305","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/BJ20070664","article-title":"Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity","volume":"406","author":"Li","year":"2007","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0310","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.atherosclerosis.2007.06.028","article-title":"A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia","volume":"197","author":"Marais","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0315","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0320","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0325","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0330","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40256-015-0119-2","article-title":"Impact of ezetimibe alone or in addition to a statin on plasma PCSK9 concentrations in patients with type 2 diabetes and hypercholesterolemia: A pilot study","volume":"15","author":"Miyoshi","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0335","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0340","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0345","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1194\/jlr.M011791","article-title":"Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice","volume":"52","author":"Mullick","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.abb.2003.09.011","article-title":"Functional characterization of Narc 1, a novel proteinase related to proteinase K","volume":"420","author":"Naureckiene","year":"2003","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0355","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1194\/jlr.M011445","article-title":"A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo","volume":"52","author":"Ni","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0360","author":"NIH Medline Plus"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0365","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-pharmtox-011613-140025","article-title":"Targeting PCSK9 for hypercholesterolemia","volume":"54","author":"Norata","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0370","author":"ODYSSEY Alternative trial"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0375","author":"ODYSSEY Outcomes trial"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0380","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.repc.2014.07.007","article-title":"LDL apheresis in the treatment of familial hypercholesterolemia: Experience of Hospital Santo Antonio, Porto","volume":"34","author":"Palma","year":"2015","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0385","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3945\/an.113.005181","article-title":"From cholesterogenesis to steroidogenesis: Role of riboflavin and flavoenzymes in the biosynthesis of vitamin D","volume":"5","author":"Pinto","year":"2014","journal-title":"Adv Nutr"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0390","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol","volume":"15","author":"Piper","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0395","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2005.08.015","article-title":"Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia","volume":"186","author":"Pisciotta","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0400","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0405","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0410","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0415","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0420","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jacl.2014.08.005","article-title":"Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia","volume":"9","author":"Raper","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0425","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0430","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/clc.22327","article-title":"Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40mg) or rosuvastatin (10 or 20mg): Design and rationale of the ODYSSEY OPTIONS studies","volume":"37","author":"Robinson","year":"2014","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0435","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0440","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0445","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0450","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0455","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/CRD.0000000000000025","article-title":"Circulating levels of proprotein convertase subtilisin kexin type 9 are elevated by fibrate therapy: A systematic review and meta-analysis of clinical trials","volume":"22","author":"Sahebkar","year":"2014","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0460","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0465","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0470","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0475","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0022-2275(20)40581-4","article-title":"Apolipoprotein B: Its role in the control of fibroblast cholesterol biosynthesis and in the regulation of its own binding to cellular receptors","volume":"20","author":"Shireman","year":"1979","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0480","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jacl.2012.05.004","article-title":"Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering","volume":"6","author":"Sniderman","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0485","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0490","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0495","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0500","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12944-015-0020-7","article-title":"Reduced cholesterol is associated with the depressive-like behavior in rats through modulation of the brain 5-HT1A receptor","volume":"14","author":"Sun","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0505","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/13543784.2014.922950","article-title":"Investigational therapies for the treatment of atherosclerosis","volume":"23","author":"Tomkin","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0510","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MOL.0b013e32833af4c1","article-title":"Apolipoprotein B synthesis inhibition: Results from clinical trials","volume":"21","author":"Visser","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0515","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: A randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0520","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0525","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0304-4157(85)90011-5","article-title":"Cholesterol and the cell membrane","volume":"822","author":"Yeagle","year":"1985","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0530","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0535","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pharmthera.2016.04.011_bb0540","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1194\/jlr.M024455","article-title":"Cholesterol level influences opioid signaling in cell models and analgesia in mice and humans","volume":"53","author":"Zheng","year":"2012","journal-title":"J Lipid Res"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816300572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816300572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T10:52:47Z","timestamp":1655635967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816300572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":108,"alternative-id":["S0163725816300572"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.04.011","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}